Tech Stocks Rebound From Heavy Losses Before Big Earnings Reports; Apple, Lilly Eye Buy PointsInvestors Business Daily • 10/19/26
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?Zacks Investment Research • 10/19/26
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are WinningMarketBeat • 10/19/26
Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitisPRNewsWire • 10/19/26
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressPRNewsWire • 10/18/26
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg HigherThe Motley Fool • 10/16/26
A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything24/7 Wall Street • 10/16/26
Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too?The Motley Fool • 10/16/26
Big pharma stocks near all-time highs as tech selloff pushes investors toward safer betsMarket Watch • 10/15/26
Eli Lilly Says New Drug Drives Comprehensive Disease Control in Ulcerative Colitis PatientsBenzinga • 10/15/26
Lilly confirms date and conference call for third-quarter 2026 financial results announcementPRNewsWire • 10/15/26
New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one yearPRNewsWire • 10/15/26
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/13/26
Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests24/7 Wall Street • 10/13/26
Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff24/7 Wall Street • 10/13/26
Eli Lilly Reports Earnings on Oct. 29. Here's Why the Retatrutide Story Matters More Than the Quarter.The Motley Fool • 10/13/26
Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued.The Motley Fool • 10/13/26